deferoxamine has been researched along with lenalidomide in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cosler, LE; Ferro, SA; Greenberg, PL; Lyman, GH | 1 |
| Altés, A; De Paz, R; del Cañizo, C; López Arrieta, JM | 1 |
1 review(s) available for deferoxamine and lenalidomide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for deferoxamine and lenalidomide
| Article | Year |
|---|---|
The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.
Topics: Anemia; Antineoplastic Agents; Azacitidine; Cost of Illness; Costs and Cost Analysis; Darbepoetin alfa; Decision Support Techniques; Deferoxamine; Drug Costs; Drug Therapy; Epoetin Alfa; Erythropoietin; Hematinics; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Practice Guidelines as Topic; Recombinant Proteins; Siderophores; Thalidomide; United States | 2008 |
[Myelodysplastic syndrome in the elderly: comprehensive geriatric assessment and therapeutic recommendations].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Blood Transfusion; Decision Support Techniques; Deferoxamine; Erythropoietin; Health Status Indicators; Humans; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Siderophores; Thalidomide | 2012 |